NP_068839.1
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
18,283 Da
NCBI Official Full Name
integral membrane protein 2B
NCBI Official Synonym Full Names
integral membrane protein 2B
NCBI Official Synonym Symbols
BRI; FBD; ABRI; BRI2; E25B; E3-16; imBRI2; BRICD2B [Similar Products]
NCBI Protein Information
integral membrane protein 2B; immature BRI2; ABri/ADan amyloid peptide; transmembrane protein BRI; BRICHOS domain containing 2B
UniProt Protein Name
Integral membrane protein 2B
UniProt Synonym Protein Names
Immature BRI2; imBRI2; Protein E25B; Transmembrane protein BRI; Bri
UniProt Synonym Gene Names
UniProt Entry Name
ITM2B_HUMAN
NCBI Summary for ITM2B
Amyloid precursor proteins are processed by beta-secretase and gamma-secretase to produce beta-amyloid peptides which form the characteristic plaques of Alzheimer disease. This gene encodes a transmembrane protein which is processed at the C-terminus by furin or furin-like proteases to produce a small secreted peptide which inhibits the deposition of beta-amyloid. Mutations which result in extension of the C-terminal end of the encoded protein, thereby increasing the size of the secreted peptide, are associated with two neurogenerative diseases, familial British dementia and familial Danish dementia. [provided by RefSeq, Oct 2009]
UniProt Comments for ITM2B
ITM2B: Plays a regulatory role in the processing of the beta- amyloid A4 precursor protein (APP) and acts as an inhibitor of the beta-amyloid peptide aggregation and fibrils deposition. Plays a role in the induction of neurite outgrowth. Functions as a protease inhibitor by blocking access of secretases to APP cleavage sites. Defects in ITM2B are a cause of cerebral amyloid angiopathy ITM2B-related type 1 (CAA-ITM2B1). A disorder characterized by amyloid deposition in the walls of cerebral blood vessels and neurodegeneration in the central nervous system. Cerebral amyloid angiopathy, non-neuritic and perivascular plaques and neurofibrillary tangles are the predominant pathological lesions. Clinical features include progressive mental deterioration, spasticity and muscular rigidity. ABri amyloidogenic peptide variant is cleaved at the normal furin processing site to generate peptide that accumulates in the brain and produces amyloid fibrils responsible for neuronal dysfunction and dementia. ABri peptide variant forms fibrila in vitro. Defects in ITM2B are a cause of cerebral amyloid angiopathy ITM2B-related type 2 (CAA-ITM2B2); also known as heredopathia ophthalmo-oto-encephalica. A disorder characterized by amyloid deposition in the walls of the blood vessels of the cerebrum, choroid plexus, cerebellum, spinal cord and retina. Plaques and neurofibrillary tangles are observed in the hippocampus. Clinical features include progressive ataxia, dementia, cataracts and deafness. ADan amyloidogenic peptide variant is cleaved at the normal furin processing site to generate peptide that accumulates in the brain and produces amyloid fibrils responsible for neuronal dysfunction and dementia. Belongs to the ITM2 family.
Protein type: Membrane protein, integral
Chromosomal Location of Human Ortholog: 13q14.3
Cellular Component: Golgi apparatus; extracellular space; membrane; intracellular membrane-bound organelle; extracellular region; plasma membrane; endosome membrane
Molecular Function: protein binding; beta-amyloid binding; ATP binding
Biological Process: nervous system development; negative regulation of amyloid precursor protein biosynthetic process
Disease: Cerebral Amyloid Angiopathy, Itm2b-related, 2; Cerebral Amyloid Angiopathy, Itm2b-related, 1; Retinal Dystrophy With Inner Retinal Dysfunction And Ganglion Cell Abnormalities
Research Articles on ITM2B
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with ITM2B elisa kit
Pathways associated with ITM2B elisa kit
Diseases associated with ITM2B elisa kit
Organs/Tissues associated with ITM2B elisa kit
|